Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00541242 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 586
- Enrollment target
NCT00541242: Completed Phase 4 study, sponsored by Allergan.
NCT00541242 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 586 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00541242, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 586 participants
- Enrollment target
Study Summary
The study will compare the safety and efficacy of Bimatoprost and Latanoprost in patients with glaucoma or ocular hypertension
Primary Outcome
Change from Baseline in mean diurnal IOP. IOP is a measurement of the fluid pressure inside the eye. Mean diurnal IOP is the average of the IOP values of both eyes at each time point measured at 8AM, 12PM and 4PM. For each eye, the IOP was either the average of the 2 measurements, or, if a third measurement was required, the median of the 3 measurements. A negative number change from Baseline indicated a reduction in IOP.
Interventions
- DRUG bimatoprost 0.03% eye drops
- DRUG latanoprost 0.005% eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 586 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
What the finished NCT00541242 record still lists
NCT00541242 is an interventional study that assigns participants to a tested intervention. The registered 586 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (13% higher).
The record links to 0 conditions, and to 2 interventions - of which bimatoprost 0.03% eye drops is the first listed.
NCT00541242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00541242 about?
NCT00541242 is a clinical study titled "Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension". The study will compare the safety and efficacy of Bimatoprost and Latanoprost in patients with glaucoma or ocular hypertension
What is the current status of trial NCT00541242?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 586 participants. The study started on 2007-12. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00541242?
The interventions under investigation include: bimatoprost 0.03% eye drops (DRUG), latanoprost 0.005% eye drops (DRUG).
Who is sponsoring clinical trial NCT00541242?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00541242's enrollment target sits among peer trials
586 148th of 2000 higher than 1,853 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134260 · 586 participants · Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- NCT06100770 · 586 participants
Aveir AR Coverage With Evidence Development (CED) Study
- NCT06183281 · 586 participants · NA
Integrating Nonpharmacologic Strategies for Pain With Inclusion, Respect, and Equity
- NCT06976203 · 586 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia